Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance

Eur J Med Res. 2010 Oct 25;15(10):448-51. doi: 10.1186/2047-783x-15-10-448.


Resistance to cisplatin in the course of chemotherapy contributes to the poor prognosis of small cell lung cancer (SCLC). B cell lymphoma-2 is the founding member of a large family of proteins that either promote or inhibit apoptosis. We aimed at investigating if the pro-apoptotic members Bad, Bax, Bim and Bid are involved in cisplatin-resistance. - Cisplatin-resistance in the SCLC cell line H1339 was induced by repetitive exposure to cisplatin. Protein expression was quantified by Western Blot and immuno-fluorescence analysis. Protein expression was altered using siRNA interference. - Four cycles of 0.5 μg/ml cisplatin led to partial cisplatin-resistance in H1339 cells. The expression of Bad, Bim and Bid was comparable in naive and resistant cells while the expression of Bax was reduced in the resistant clone. But, reducing Bax expression in naive cells did not lead to altered cisplatin sensitivity neither in H1339 nor in H187 SCLC cells. - We conclude that the reduced Bax expression after exposure to cisplatin is not sufficient to induce cisplatin-resistance in SCLC cells.

MeSH terms

  • Actins / genetics
  • Carcinoma, Small Cell / drug therapy
  • Carcinoma, Small Cell / genetics*
  • Carcinoma, Small Cell / pathology
  • Cell Line, Tumor / drug effects
  • Cell Survival / drug effects
  • Cisplatin / therapeutic use*
  • Drug Resistance, Neoplasm / drug effects*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • RNA, Small Interfering / genetics
  • Transfection
  • Tumor Cells, Cultured / pathology
  • bcl-2-Associated X Protein / genetics*


  • Actins
  • RNA, Small Interfering
  • bcl-2-Associated X Protein
  • Cisplatin